Tumour markers

Breast cancer Ca 15-3 can be ↑ in people with breast cancer & also in other conditions as liver cirrhosis , benign ovarian and breast disease Metastatic breast cancer - testing for CA 15-3 , CA 27.29 and or CEA + symptoms / imaging may be employed to monitor growth of recurrent or metastatic disease

Colorectal cancer Does not help as a screening tool ( CEA ) but can help monitor effectiveness of therapy CEA low diagnostic ability but high pre-treatment levels are correlated with stage of the disease. CEA can also be raised in non cancer conditions as gastritis , peptic ulcer disease , diverticulitis , liver disease , COPD , diabetes and other inflammatory states CEA , CA 50 , CA 19-5 , CA 19-9, CA 72-4 , Chromogranin A

Gastro-intestinal tumours CA 72-4 elevated in a number of human adenocarcinomas , studies have shown that it may play a role in disease monitoring of pancreatic , ovarian and colorectal carcinomas Chromogranin A - has been used for assessment of neuro-endocrine tumours and used traditionally in the management of patients with tumors of gastro-enteropancreatic origin CA 19-9 - predictive role in case of metastatic or recurrent cases and...